Stay updated on Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.

Latest updates to the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page
- Check7 days agoChange DetectedThe page's Revision label updated from v3.3.3 to v3.3.4, indicating a backend/site version change. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedA Locations section listing participating sites across the United States, Australia, Canada, and Poland was added, and location listings were revised (some entries removed).SummaryDifference2%

- Check57 days agoChange DetectedPubMed publications are now described as automatically populated from PubMed and may not all relate to the study. The revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.4%

- Check64 days agoChange DetectedThe government funding/operating status notice was removed; the study details and enrollment information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check78 days agoChange DetectedThe changes appear to be minor UI/layout adjustments with no substantive changes to core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check107 days agoChange DetectedUpdated version to v3.2.0 and added a government operating-status notice for NIH Clinical Center, directing users to cc.nih.gov and opm.gov.SummaryDifference2%

Stay in the know with updates to Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.